Literature DB >> 26858272

High carriage rate of ESBL-producing Enterobacteriaceae at presentation and follow-up among travellers with gastrointestinal complaints returning from India and Southeast Asia.

Isabel Barreto Miranda1, Ralf Ignatius2, Roland Pfüller3, Barbara Friedrich-Jänicke4, Florian Steiner5, Matthias Paland5, Sebastian Dieckmann4, Katharina Schaufler6, Lothar H Wieler7, Sebastian Guenther6, Frank P Mockenhaupt8.   

Abstract

BACKGROUND: International travel contributes to the spread of multidrug-resistant microorganisms including extended spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE). We assessed the proportion of faecal carriers of ESBL-PE among 211 patients with gastrointestinal symptoms who returned to Berlin, Germany, after international travel.
METHODS: ESBL-PE were screened for on chromogenic agar, antimicrobial susceptibility testing was performed, and ESBL-genes were genotyped. Travel-related data were assessed by questionnaire.
RESULTS: Diarrhoea, abdominal pain and nausea were the main symptoms. Half of the travellers carried ESBL-PE (97% Escherichia coli); the proportion was highest for returnees from India (72%) and mainland Southeast Asia (59%), and comparatively lower for Africa (33%) and Central America (20%). Co-resistance to fluoroquinolones (particularly in isolates from India), gentamicin and cotrimoxazole was frequent but all isolates were carbapenem-susceptible. ESBL-PE carriage decreased with increasing timespan from return to presentation, and with age. At revisit of initially ESBL-PE positive patients half a year later, 28% (17/61) of the individuals were still carriers, CTX-M groups being congruent with the initial isolates. CTX-M groups 9 and 1/9, vegetarian diet and cat ownership tended to be associated with ESBL-PE carriage upon revisit.
CONCLUSIONS: Travellers, particularly those returning from India and Southeast Asia, constitute a relevant source of potential spread of ESBL-PE. Carriage declines over time but ESBL-PE persist for at least 6 months in a substantial proportion of individuals. Both genetic characteristics of the bacteria and lifestyle factors seem to contribute to persistent carriage of ESBL-PE. A recent, extra-European travel history argues for ESBL-PE screening and contact precautions for patients admitted to hospital. © International Society of Travel Medicine, 2016. All rights reserved. Published by Oxford University Press. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CTX-M; ESBL; antimicrobial resistance; extended-spectrum beta-lactamase; traveller

Mesh:

Substances:

Year:  2016        PMID: 26858272     DOI: 10.1093/jtm/tav024

Source DB:  PubMed          Journal:  J Travel Med        ISSN: 1195-1982            Impact factor:   8.490


  30 in total

Review 1.  Travel and the Spread of Drug-Resistant Bacteria.

Authors:  Kevin L Schwartz; Shaun K Morris
Journal:  Curr Infect Dis Rep       Date:  2018-06-29       Impact factor: 3.725

Review 2.  Multiresistant Gram-Negative Pathogens—A Zoonotic Problem.

Authors:  Robin Köck; Caroline Herr; Lothar Kreienbrock; Stefan Schwarz; Bernd-Alois Tenhagen; Birgit Walther
Journal:  Dtsch Arztebl Int       Date:  2021-09-06       Impact factor: 5.594

Review 3.  Guidelines for the prevention and treatment of travelers' diarrhea: a graded expert panel report.

Authors:  Mark S Riddle; Bradley A Connor; Nicholas J Beeching; Herbert L DuPont; Davidson H Hamer; Phyllis Kozarsky; Michael Libman; Robert Steffen; David Taylor; David R Tribble; Jordi Vila; Philipp Zanger; Charles D Ericsson
Journal:  J Travel Med       Date:  2017-04-01       Impact factor: 8.490

4.  Multidrug-resistant bacteria as intestinal colonizers and evolution of intestinal colonization in healthy university students in Portugal.

Authors:  Raquel Mota; Marisa Pinto; Josman Palmeira; Daniela Gonçalves; Helena Ferreira
Journal:  Access Microbiol       Date:  2020-11-25

Review 5.  The antimicrobial resistance travel tool, an interactive evidence-based educational tool to limit antimicrobial resistance spread.

Authors:  Fabiana Arieti; Alessia Savoldi; Nithya Babu Rejendran; Marcella Sibani; Maela Tebon; Maria Diletta Pezzani; Anna Gorska; Teresa M Wozniak; Evelina Tacconelli
Journal:  J Travel Med       Date:  2022-07-14       Impact factor: 39.194

6.  Prolonged colonisation with Escherichia coli O25:ST131 versus other extended-spectrum beta-lactamase-producing E. coli in a long-term care facility with high endemic level of rectal colonisation, the Netherlands, 2013 to 2014.

Authors:  Ilse Overdevest; Manon Haverkate; Jacobien Veenemans; Yvonne Hendriks; Carlo Verhulst; Ans Mulders; Willemijn Couprie; Martin Bootsma; James Johnson; Jan Kluytmans
Journal:  Euro Surveill       Date:  2016-10-20

7.  Trial Evaluating Ambulatory Therapy of Travelers' Diarrhea (TrEAT TD) Study: A Randomized Controlled Trial Comparing 3 Single-Dose Antibiotic Regimens With Loperamide.

Authors:  Mark S Riddle; Patrick Connor; Jamie Fraser; Chad K Porter; Brett Swierczewski; Emma J Hutley; Brook Danboise; Mark P Simons; Christine Hulseberg; Tahaniyat Lalani; Ramiro L Gutierrez; David R Tribble
Journal:  Clin Infect Dis       Date:  2017-11-29       Impact factor: 9.079

8.  Antibiotic resistance during and beyond COVID-19.

Authors:  David M Livermore
Journal:  JAC Antimicrob Resist       Date:  2021-06-15

9.  Polyclonal Intestinal Colonization with Extended-Spectrum Cephalosporin-Resistant Enterobacteriaceae upon Traveling to India.

Authors:  João Pires; Esther Kuenzli; Sara Kasraian; Regula Tinguely; Hansjakob Furrer; Markus Hilty; Christoph Hatz; Andrea Endimiani
Journal:  Front Microbiol       Date:  2016-07-12       Impact factor: 5.640

10.  High Gastrointestinal Colonization Rate with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Hospitalized Patients: Emergence of Carbapenemase-Producing K. pneumoniae in Ethiopia.

Authors:  Kassu Desta; Yimtubezinash Woldeamanuel; Aklilu Azazh; Halima Mohammod; Dawit Desalegn; Damte Shimelis; Dereje Gulilat; Biruk Lamisso; Eyasu Makonnen; Alemayehu Worku; Kerstin Mannerqvist; Johan Struwe; Olov Aspevall; Eleni Aklillu
Journal:  PLoS One       Date:  2016-08-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.